Literature DB >> 18570280

Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models.

Rose Hayeshi1, Collen Masimirembwa, Stanley Mukanganyama, Anna-Lena B Ungell.   

Abstract

The lipophilic weak base amodiaquine is an antimalarial drug that has been in use for over 40 years. Little is known of amodiaquine's mechanism of transport across membranes. Transport experiments of amodiaquine in Caco-2 cells showed a low recovery of 30% and rapid disappearance from the apical chamber. Compounds structurally similar to amodiaquine, and those affecting non-specific binding of amodiaquine or the pH of the system, were tested to unravel the mechanism behind these observations. Chloroquine and ammonium chloride increased the transmonolayer permeability of amodiaquine and decreased its accumulation in Caco-2 cells, whereas BSA had no effect. Chloroquine and BSA decreased plastic binding whereas ammonium chloride had no effect. This suggests that amodiaquine is trapped in acidic cell compartments such as lysosomes. Amodiaquine was also trapped in rat intestinal tissue. In addition, permeability from the apical to basolateral direction was significantly higher, suggesting an active uptake over the apical membrane of the rat tissue. It can be concluded that amodiaquine is trapped in acidic cell compartments due to its base properties and recovery may be improved by the use of ammonium chloride rather than BSA in transport experiments. Further studies are required to confirm whether amodiaquine is actively absorbed in the intestine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570280     DOI: 10.1002/bdd.616

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction.

Authors:  Violetta N Pivtoraiko; Adam J Harrington; Burton J Mader; Austin M Luker; Guy A Caldwell; Kim A Caldwell; Kevin A Roth; John J Shacka
Journal:  J Neurochem       Date:  2010-06-01       Impact factor: 5.372

Review 2.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

3.  Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine.

Authors:  Nan Zheng; Xinyuan Zhang; Gus R Rosania
Journal:  J Pharmacol Exp Ther       Date:  2010-12-14       Impact factor: 4.030

4.  Effects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.

Authors:  Brad T Benedetti; Erica J Peterson; Peyman Kabolizadeh; Alberto Martínez; Ralph Kipping; Nicholas P Farrell
Journal:  Mol Pharm       Date:  2011-05-16       Impact factor: 4.939

5.  Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Authors:  Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2013-02-01       Impact factor: 3.922

6.  Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Authors:  Tesia Bobrowski; Lu Chen; Richard T Eastman; Zina Itkin; Paul Shinn; Catherine Chen; Hui Guo; Wei Zheng; Sam Michael; Anton Simeonov; Matthew D Hall; Alexey V Zakharov; Eugene N Muratov
Journal:  bioRxiv       Date:  2020-06-30

7.  Identification of drugs inducing phospholipidosis by novel in vitro data.

Authors:  Markus Muehlbacher; Philipp Tripal; Florian Roas; Johannes Kornhuber
Journal:  ChemMedChem       Date:  2012-09-03       Impact factor: 3.466

8.  Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds.

Authors:  Kasiram Katneni; Thao Pham; Jessica Saunders; Gong Chen; Rahul Patil; Karen L White; Nada Abla; Francis C K Chiu; David M Shackleford; Susan A Charman
Journal:  Pharm Res       Date:  2018-09-17       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.